Skip to main content

Table 1 Patient characteristics

From: Prognostic value at 5 years of microvascular obstruction after acute myocardial infarction assessed by cardiovascular magnetic resonance

Clinical Charcteristics

All (n = 107)

eMVO + (n = 74)

eMVO - (n = 33)

p-value

Female, n(%)

20 (18.5)

13 (17.6)

7 (21.2)

.421

Age, years

56.8 ± 12.0

57.8 ± 12.2

54.6 ± 11.3

.217

BMI, kg/m²

25.5 ± 4.0

25.8 ± 2.7

24.9 ± 5.8

.250

Hypertension, n (%)

64 (59.8)

48 (65.8)

15 (45.5)

.040*

Hypercholesterinemia, n(%)

87 (81.3)

61 (83.6)

26 (78.8)

.367

Smoking, n(%)

60 (56.1)

37 (50.7)

23 (69.7)

.052

Diabetes mellitus, n(%)

9 (8.4)

7 (9.6)

2 (6.1)

.427

Family history for CVD, n(%)

21 (19.6)

14 (19.2)

7 (21.2)

.500

Pain-to-balloon, min [median]

210 (IQR: 120–330)

210 (IQR: 150–338)

180 (IQR: 60–270)

.553

Prehospital lysis, n (%)

12 (11.1)

7 (9.5)

4 (12.1)

.456

TIMI pre PCI, n(%)

   

.471

MEAN

 

0.38 ± 0.8

0.58 ± 0.8

.292

0

61 (72.6)

46 (76.7)

15 (62.5)

 

1

10 (11.9)

6 (10.0)

4 (16.7)

 

2

12 (14.3)

7 (11.7)

5 (20.8)

 

3

1(1.2)

1 (1.7)

0 (0)

 

TIMI post PCI, n(%)

    

MEAN

 

2.95 ± 0.4

2.84 ± 0.5

.260

0

1 (1.2)

1 (0)

0 (0)

 

1

1 (1.2)

0 (0)

1 (4.0)

 

2

2 (2.3)

0 (0)

2 (8.0)

 

3

82 (95.3)

60 (98.4)

22 (88.0)

 

CKmax, U/l

2460.3 ± 2026.7

2844.8 ± 1992.7

1492.4 ± 1802.5

.002**

cTnTmax, μg/ml

6.96 ± 5.31

8.02 ± 5.19

4.30 ± 4.71

.001**

ST-Resolution, n(%)

52 (80)

33 (78.6)

22 (81.8)

.517

Infarct size, g

22.0 ± 16.0

24.9 ± 15.2

15.5 ± 16.1

.006**

Infarct transmurality, n(%)

   

.002**

MEAN

 

98.2 ± 6.5

85 ± 25.1

<.001**

0-25

3 (3.0)

0

3 (10.0)

 

25-50

2 (2.0)

0

2 (6.7)

 

50-75

10 (10.0)

5 (7.1)

5 (16.7)

 

75-100

85 (85.0)

65 (92.9)

20 (66.7)

 

Ejection fraction, %

41.1 ± 11.2

39.2 ± 11.4

46.1 ± 8.9

.005**

Early MVO, n(%)

74 (69.2)

   

Late MVO, n(%)

63 (58.9)

59 (79.7)

4 (12.1)

<.001**

NYHA class at follow up, n(%)

    

MEAN

 

1.5 ± 0.8

1.2 ± 0.5

.072

I

73 (73.0)

46 (67.6)

26 (83.9)

 

II

16 (16.0)

12 (17.6)

4 (12.9)

 

III

9 (9.0)

8 (11.7)

1 (3.2)

 

IV

2 (2.0)

2 (2.9)

0 (0)

 

CCS class at follow-up, n(%)

    

MEAN

 

0.43 ± 0.8

0.39 ± 0.7

.808

0

71 (71.0)

48 (70.6)

22 (71.0)

 

I

19 (19.0)

13 (19.1)

6 (19.4)

 

II

9 (9.0)

6 (8.8)

3 (9.7)

 

III

0 (0.0)

0 (0)

0 (0)

 

IV

1 (1.0)

1 (1.4)

0 (0)

 
  1. The table is showing the clinical characteristics of the whole study cohort and patients with or without MVO. P-values are given between patients with and patients without MVO (*p < 0.05, **p < 0.01). Early/late MVO: early microvascular obstruction, BMI: body mass index, CVD: cardiovascular disease, TIMI: thrombolysis in myocardial infarction, PCI: percutaneous coronary intervention, CKmax: maximum creatine kinase, cTnTmax: maximum cardiac Troponin T, NYHA: New York Heart Association, CCS: Canadian Cardiovascular Society.